Czechia's medicines regulator. Besides overseeing medicines and authorising clinical trials, it decides the maximum price of a medicine and whether and on what terms public health insurance pays for it.
SÚKL describes itself as an administrative authority established by Act 79/1997 Coll., an organisational unit of the state under the Ministry of Health, with its seat at Šrobárova 49/48, Prague 10. Its predecessor, the Institute for the Examination of Medicines, was set up in 1918, and SÚKL was separated from the National Institute of Public Health by a Ministry of Health decree of 24 April 1952. Its disclosure page lists MUDr. Tomáš Boráň as director from 2 May 2024.
Since 1 January 2008 Act 48/1997 Coll. has given SÚKL the setting of maximum prices and of the level and conditions of reimbursement of medicines. Under section 39b it weighs, among other things, therapeutic effect and safety, the severity of the disease, the applicant's cost-effectiveness and budget impact analyses, substitutability and the price of alternatives, professional guidelines, and any published EU joint clinical assessment report. Section 39d lets it grant a highly innovative medicine temporary reimbursement for 3 years, renewable for at most 2 more, without the cost-effectiveness condition. Under section 51 of the Medicines Act 378/2007 Coll. it assesses applications to authorise clinical trials under the EU clinical trials regulation and is the national contact point. Under section 49 of the same act it gives its opinion on specific treatment programmes that allow an unregistered medicine to be used, which the Ministry of Health approves.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/